Virus-like particle T cell activation via CD86 and CD3
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating engineered T-cell products are costly due to the use of mitogenic antibodies and beads, which are single-use consumables, and complex engineering of viral envelope proteins can reduce viral titre and require complex peptide display engineering.
Innovation Solution
Virus-like particles (VLPs) expressing a CD3-binding protein and a protein comprising the extracellular domain of CD86 are used to activate T cells, incorporating these proteins into the viral envelope during budding, preserving viral titre and improving T-cell activation and expansion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If soluble mitogenic monoclonal antibodies are added to cell culture for T cell activation, then T cell activation is achieved, but production cost increases due to single-use consumables
Solution Approach 1:
The patent creates virus-like particles that copy the T cell activating function of soluble antibodies by displaying anti-TCR/CD3 and anti-CD28 antibodies on the viral envelope surface. These VLPs can be produced in bulk and reused, replacing single-use soluble antibodies and reducing production costs while maintaining reliable T cell activation
Solution Approach 2:
The patent combines multiple functional components into a composite viral envelope structure that includes both anti-TCR/CD3 antibodies and anti-CD28 antibodies integrated into the VLP surface. This composite structure provides synergistic T cell activation while being producible as a reusable material rather than requiring separate single-use antibody additions
2Reliability
If anti-TCR/CD3 mAb and anti-CD28 mAb are attached to a bead for T cell activation, then T cell activating properties are improved, but production cost increases due to single-use consumables
Solution Approach 1:
The patent copies the bead-based antibody attachment concept by integrating antibodies directly into the viral envelope structure. Instead of using physical beads as carriers, the VLPs themselves serve as the carrier platform, eliminating the need for separate bead consumables while maintaining improved T cell activating properties and enabling bulk production
3Reliability
If lentiviral envelope protein is directly engineered to display CD3 agonist OKT3 on virion surface, then T cell activation is achieved, but viral titre is reduced
Solution Approach 1:
The patent segments the T cell activation function from the viral envelope glycoprotein by expressing anti-TCR/CD3 and anti-CD28 antibodies as separate transmembrane proteins in the producer cell that are incorporated into the VLP envelope. This segmentation preserves the reading frame of the viral envelope and maintains viral titre while achieving T cell activation through the displayed antibodies on the VLP surface
4Adaptability or versatility
If complex engineering is performed on viral envelope protein to display discrete peptides, then peptide display function is achieved, but device complexity increases
Solution Approach 1:
The patent creates a universal VLP platform where the viral envelope can display multiple different transmembrane proteins (such as anti-TCR/CD3 antibodies, anti-CD28 antibodies, and other cytokines) through a standardized incorporation mechanism. This multi-functional platform eliminates the need for complex discrete engineering for each peptide while maintaining versatility in T cell activation strategies
Data Source
AI summary
The present invention provides a virus-like particle (VLP) having a viral envelope which comprises: (i) a membrane protein comprising the extracellular domain of CD86; and (ii) a CD3-binding membrane protein. The VLP may be used to activate T cells prior to viral transduction.